Do platinum salts fit all triple negative breast cancers?

Cancer Treat Rev. 2016 Jul:48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients. In recent years, several randomised trials have been conducted to evaluate platinum efficacy in both early-stage and advanced TNBC, with conflicting results especially for long-term outcomes. Experimental studies are now focusing on identifying biomarkers of response to help selecting patients who may benefit most from platinum-based therapies, including BRCA1/2 mutational status and genomic instability signatures (such as HRD-LOH or HRD-LST scores). A standard therapy for TNBC is still missing and platinum-based regimens represent an emerging therapeutic option for selected patients with a defect in the homologous recombination repair system. The identification of these patients through validated biomarker assays will be crucial to optimize the use of currently approved agents in TNBC.

Keywords: BRCAness; Carboplatin; Cisplatin; Triple negative breast cancer.

Publication types

  • Review

MeSH terms

  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Humans
  • Organoplatinum Compounds / chemistry
  • Organoplatinum Compounds / therapeutic use*
  • Rad51 Recombinase / genetics
  • Randomized Controlled Trials as Topic
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / genetics

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Organoplatinum Compounds
  • RAD51 protein, human
  • Rad51 Recombinase